首页> 外国专利> New Fusion Proteins and Their Use as Hepatitis C Vaccine

New Fusion Proteins and Their Use as Hepatitis C Vaccine

机译:新融合蛋白及其作为丙型肝炎疫苗的用途

摘要

An immunogenic fusion protein includes at least, on the C-terminal side, a first peptide composed of the S protein deleted of the transmembrane domain thereof located at the N-terminal end thereof, of a hepatitis B virus (HBV) isolate, and on the N-terminal side, a second peptide composed of the transmembrane domain and of the ectodomain of at least one envelope protein of a hepatitis C virus (HCV) isolate. A hybrid nucleic acid molecule encoding the fusion protein, and a vector including the hybrid nucleic acid molecule, a subviral particle including the fusion protein, an immunogenic composition including at least the fusion protein, or at least the hybrid nucleic acid molecule, or at least the subviral particle, and a cell line for the production of the fusion protein, or of the hybrid nucleic acid molecule, or of the subviral particle are described.
机译:免疫原性融合蛋白至少在其C-末端侧包括第一肽,该第一肽由位于其N-末端的其跨膜结构域中缺失的S蛋白组成,并由乙型肝炎病毒分离。在N-末端侧,第二种肽由丙型肝炎病毒(HCV)分离株的至少一种包膜蛋白的跨膜结构域和胞外结构域组成。编码所述融合蛋白的杂合核酸分子,以及包含所述杂合核酸分子的载体,包含所述融合蛋白的亚病毒颗粒,至少包含所述融合蛋白或至少包含所述杂合核酸分子的免疫原性组合物,或至少包含所述杂合核酸分子的免疫原性组合物。描述了亚病毒颗粒,以及用于产生融合蛋白,杂合核酸分子或亚病毒颗粒的细胞系。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号